2021 | Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer | Even C.; Wang H.-M.; Li S.-H.; Ngan R.K.-C.; Dechaphunkul A.; Zhang L.; Yen C.-J.; Chan P.C.; Chakrabandhu S.; Ma B.B.Y.; Tanasanvimon S.; Lee V.H.F.; PEI-JEN LOU ; Li Z.; Spira A.I.; Sukari A.; Guigay J.; McCune S.; Gonzalez-Maffe J.; Szpakowski S.; Yao Y.; Liang H.; Mataraza J.; Sechaud R.; Manenti L.; Lim D.W.-T. | Clinical Cancer Research | 30 | 29 | |